Genomic Testing | Clinical

October 17, 2022

As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.

August 26, 2022

According to experts, routine biomarker testing has become a standard part of care for several common tumor types.

July 29, 2022

Lori J. Wirth, MD, discusses a new assay with the ability to perform DNA and RNA sequencing to better detect gene fusions.

July 11, 2022

Specific biliary tract cancer clusters have distinct clinical and biologic features which may provide opportunities for therapeutic development.

June 14, 2022

A tumor genomic profiling program has shown feasibility and clinical impact for pediatric patients who are high-risk de novo and relapsed/refractory.

June 01, 2022

Allegheny Health Network Cancer Institute will be collaborating with Illumina to evaluate the impact of in-house comprehensive genomic profiling to enhance patient care.

May 26, 2022

Allegheny Health Network and Illumina, Inc. announced a collaborative effort to assess their in-house comprehensive genomic testing to analyze the role of genetic tests in improving cancer care.

May 16, 2022

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

April 16, 2022

Improving our diagnostic and prognostic testing capabilities is one of the most important and exciting ways to improve how we care for patients with cancer, according to John M. Burke, MD.

April 14, 2022

Many oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.